Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

| More on:
ecommerce asx shares represented by santa doing online shopping on laptop

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Despite previous challenges, CSL offers potential growth and stability with improving plasma collections and strong demand for its healthcare products.
  • Known for its notable dividend yield of approximately 11%, Accent presents an attractive option for income-focused investors keen on retail sector resilience.
  • Both CSL and Accent are compelling options for those seeking either long-term growth or immediate income as the year draws to a close.

As Christmas approaches, plenty of investors start thinking about where to put fresh money to work before the new year. I am no different. With markets still a bit choppy and sentiment mixed across sectors, I have been focusing on quality businesses where the risk-reward balance looks attractive heading into 2026.

Two ASX shares are standing out to me right now, despite sitting at opposite ends of the market. For different reasons, both are worth a closer look.

CSL Ltd (ASX: CSL)

The CSL share price has had a tough run over the past year and is trading around $175, well below the levels investors had become used to. Softer profit guidance, higher costs, and a slower-than-expected recovery in plasma collections weighed on sentiment, and the market did not take kindly to that.

That being said, the long-term story has not broken. Plasma collections have been improving, Seqirus continues to perform solidly, and CSL Vifor is starting to settle after a challenging integration period. Cost discipline is also coming into focus, which is usually the first step toward margin recovery.

Several brokers continue to describe CSL as oversold, with price targets well above current levels. For a global healthcare leader with a long track record of growth, a strong balance sheet, and solid demand for immunoglobulin and vaccines, the current share price is starting to look far more appealing than it did a year ago.

If CSL can show steadier execution across FY26, the share price could start to find support.

Accent Group Ltd (ASX: AX1)

At the other end of the spectrum sits Accent, with its share price trading around 90 cents. The footwear retailer owns well-known brands such as Platypus, Hype DC and The Athlete's Foot, and it has built a strong omnichannel business across Australia and New Zealand.

What really stands out here is income. Accent paid 10 cents per share in fully franked dividends over the past year, which puts the trailing yield at roughly 11% at current prices. That is a big number for an ASX 200 stock.

While retail always carries some risk, Accent has performed better than many of its peers, with resilient margins and solid digital sales. Management continues to invest in store rollouts and owned brands, which support earnings over time.

For income-focused investors who are comfortable with some volatility, Accent offers a level of yield that is hard to ignore.

Foolish Takeaway

CSL and Accent Group are very different businesses, but both stand out to me as we head into Christmas. CSL offers quality and long-term growth at a much lower price than usual, while Accent provides immediate income at an attractive yield.

For investors looking to add ideas before the year ends, these two ASX shares are well worth having on the watchlist.

Motley Fool contributor Aaron Teboneras has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Accent Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

4DMedical shares jump again today. Here's what investors liked

Commercial momentum builds following a busy quarterly update.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

I think the market is wrong about CSL shares

When a world-class business loses tens of billions in value, I think it’s worth asking whether the market has overreacted.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why is the ResMed share price jumping 7% today?

This sleep disorder treatment giant delivered another three months of strong growth.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Could Mesoblast shares hit $4.45 in 2026?

Bell Potter thinks this biotech could be cheap and heading much higher.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

This broker just upgraded this ASX healthcare stock and is predicting 30% upside

A new collaboration has sparked interest in this healthcare stock.

Read more »

A man sees some good news on his phone and gives a little cheer.
Healthcare Shares

Why this speculative ASX stock could rise 80%

Let's see what Bell Potter is saying about this small cap.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech just smashed its quarterly update. So why are its shares falling?

Immutep’s share price fell despite steady clinical progress and a major global drug deal.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is now a good time to buy the big dip in Pro Medicus shares?

A leading analyst delivers his verdict on Pro Medicus beaten down shares.

Read more »